Osteogenesis Imperfecta Foundation
Learn more about:
Related Access Program
Agios Pharmaceuticals, Inc. – Acute Myeloid Leukemia
Novartis Pharmaceuticals – FLT3-mutated Acute Myeloid Leukemia
AbbVie – Acute Myeloid Leukemia (AML)
University of California, San Francisco – Acute Myeloid Leukemia
Emory University – Acute Myeloid Leukemia
British Columbia Cancer Agency – Thyroid Cancer, Medullary
Novartis Pharmaceuticals – Acute Myeloid Leukemia (AML) With
Beijing Cancer Hospital – Thyroid Nodules
Alnylam Pharmaceuticals – Amyloidosis, Hereditary
Alnylam Pharmaceuticals – TTR-mediated Amyloidosis
Astellas Pharma Global Development, Inc. – Acute Myeloid Leukemia (AML)
The Osteogenesis Imperfecta Foundation focus on research for osteogenesis imperfecta (OI), educating key stakeholders about OI, creating more awareness about the rare disease and supporting people that are living with OI.